Catalent expands Kentucky solid dose plant even as it moves into gene therapy  

29th April 2019 Uncategorised 0

Catalent busted into the thriving gene therapy contract market with its recent $1.2 billion deal for Paragon Bioservices. While gene therapy is the shiny new thing in the CDMO world, Catalent continues to expand the traditional parts its business that currently comprise most of its global footprint.

More: Catalent expands Kentucky solid dose plant even as it moves into gene therapy  
Source: fierce